TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes
Brief Summary: The aim of this study is to compare glycemic control in pregnant women treated with insulin Detemir and pregnant women treated with NPH insulin. These women are diagnosed with gestational diabetes (GDM) in the current pregnancy or have a preexisting diagnosis of type 2 diabetes (T2DM) at the onset of pregnancy. Our hypothesis is that there is no difference between these two treatment modalities in terms of glycemic control in diabetes.


Options:
A: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Arm Label: Levemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Arm Label: NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Levemir, NPH
D: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. To analyze the clinical significance of the concentration change of vascular endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection bevacizumab


Options:
A: Arm Label: Bevacizumab+TC; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: TC:paclitaxel + carboplatin | Arm Label: TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: TC:paclitaxel + carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab+TC | Intervention Type: DRUG; Name: TC:paclitaxel + carboplatin; Assigned to Arm(s): Bevacizumab+TC, TC
B: Arm Label: Arm A: trabectedin + DOXIL; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: Arm B: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): Arm B: DOXIL
C: Arm Label: Bevacizumab combined with Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Bevacizumab combined with chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Fluzoparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: chemotherapy; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: Fluzoparib; Assigned to Arm(s): Fluzoparib
D: Arm Label: chemotherapy, avelumab and talazoparib; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy + avelumab followed by avelumab + talazoparib | Arm Label: chemotherapy, and talazoparib; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy followed by talazoparib maintenance | Arm Label: chemotherapy and bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy + bevacizumab followed by bevacizumab | Intervention Type: DRUG; Name: Chemotherapy + avelumab followed by avelumab + talazoparib; Assigned to Arm(s): chemotherapy, avelumab and talazoparib | Intervention Type: DRUG; Name: Chemotherapy followed by talazoparib maintenance; Assigned to Arm(s): chemotherapy, and talazoparib | Intervention Type: DRUG; Name: Chemotherapy + bevacizumab followed by bevacizumab; Assigned to Arm(s): chemotherapy and bevacizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. To analyze the clinical significance of the concentration change of vascular endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection bevacizumab


Options:
A: Arm Label: Bevacizumab+TC; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: TC:paclitaxel + carboplatin | Arm Label: TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: TC:paclitaxel + carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab+TC | Intervention Type: DRUG; Name: TC:paclitaxel + carboplatin; Assigned to Arm(s): Bevacizumab+TC, TC
B: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Arm Label: Chemotherapy and bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy and bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy
C: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis
Brief Summary: This is a multicenter study conducted in 2 parts:

The primary objective in Part I of this study is to determine the efficacy of BG00012 (dimethyl fumarate, DMF) on inflammatory brain magnetic resonance imaging (MRI) lesion activity (Gadolinium-enhancing lesions) when compared with placebo from 4 scans performed at Weeks 12, 16, 20, and 24 in participants with Relapsing Remitting Multiple Sclerosis (RRMS) including participants from the Asia-Pacific region.

The secondary objectives in Part I of this study in this study population are to determine whether BG00012, when compared with placebo over 24 weeks, is effective in reducing the cumulative number of new Gadolinium-enhancing lesions from Baseline to Week 24; reducing the number of new or newly enlarging T2 hyperintense lesions on brain MRI scans at Week 24 compared with Baseline.

The primary objective in Part II (open label) of this study is to evaluate the long-term safety profile of BG00012 in eligible participants from Part I.


Options:
A: Arm Label: ALKS 8700; Type: EXPERIMENTAL; Interventions: Drug: ALKS 8700 | Arm Label: Dimethyl Fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dimethyl Fumarate | Intervention Type: DRUG; Name: ALKS 8700; Assigned to Arm(s): ALKS 8700 | Intervention Type: DRUG; Name: Dimethyl Fumarate; Assigned to Arm(s): Dimethyl Fumarate
B: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Part I Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part I BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Arm Label: Part II BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part I Placebo | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): Part I BG00012, Part II BG00012

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Guiding Dreaming During Anaesthesia by Means of Communication Through Suggestions. What Influences Our Suggestions? What do Our Suggestions Influence?
Brief Summary: Hypothesis: By employing suggestions before the induction of narcosis dreams may be evoked and their content may be directed.

The main goal of suggestive techniques in the perioperative phase is to turn the content of dreams toward a favourable direction that is considered a pleasant event by the patient. So far little attention has been paid to the administration of perioperative psychological methods that may meet these requirements.

Along these lines, in the present study we intended to assess whether dream recalls can be influenced by two different psychological methods administered in the preoperative setting


Options:
A: Arm Label: Audio Relaxation technique; Type: EXPERIMENTAL; Interventions: Behavioral: Audio Relaxation Technique | Arm Label: Medical Music Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Medical Music Intervention | Arm Label: Nature Therapy without Music; Type: EXPERIMENTAL; Interventions: Behavioral: Nature Therapy without Music | Arm Label: Nature Therapy with Music; Type: EXPERIMENTAL; Interventions: Behavioral: Nature Therapy with Music | Intervention Type: BEHAVIORAL; Name: Audio Relaxation Technique; Assigned to Arm(s): Audio Relaxation technique | Intervention Type: BEHAVIORAL; Name: Medical Music Intervention; Assigned to Arm(s): Medical Music Intervention | Intervention Type: BEHAVIORAL; Name: Nature Therapy without Music; Assigned to Arm(s): Nature Therapy without Music | Intervention Type: BEHAVIORAL; Name: Nature Therapy with Music; Assigned to Arm(s): Nature Therapy with Music
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stress reduction intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stress reduction intervention; Assigned to Arm(s): 1
C: Arm Label: etomidate/sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Arm Label: propofol/sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Arm Label: propofol/propofol; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Intervention Type: OTHER; Name: control; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane | Intervention Type: OTHER; Name: suggestion; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane | Intervention Type: OTHER; Name: dreamfilm; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane
D: Arm Label: Cognitive behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): Cognitive behavioral therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
Brief Summary: The primary objective is to examine the clinical efficacy of multiple doses of nusinersen (ISIS 396443) administered intrathecally to participants with Infantile-Onset Spinal Muscular Atrophy (SMA). The secondary objectives are to examine the safety and tolerability of multiple doses of nusinersen administered intrathecally to participants with infantile-onset SMA and to examine the cerebral spinal fluid (CSF) and plasma Pharmacokinetics (PK) of multiple doses of nusinersen administered intrathecally to participants with infantile-onset SMA.


Options:
A: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
B: Arm Label: Olesoxime; Type: EXPERIMENTAL; Interventions: Drug: Olesoxime | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olesoxime; Assigned to Arm(s): Olesoxime | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A
D: Arm Label: Nusinersen 6 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Nusinersen 12 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Nusinersen 12 mg, Nusinersen 6 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
Brief Summary: The primary objective is to examine the clinical efficacy of multiple doses of nusinersen (ISIS 396443) administered intrathecally to participants with Infantile-Onset Spinal Muscular Atrophy (SMA). The secondary objectives are to examine the safety and tolerability of multiple doses of nusinersen administered intrathecally to participants with infantile-onset SMA and to examine the cerebral spinal fluid (CSF) and plasma Pharmacokinetics (PK) of multiple doses of nusinersen administered intrathecally to participants with infantile-onset SMA.


Options:
A: Arm Label: Cohort 1 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 2 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 3 (n=6); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Cohort 4 (n=10); Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Cohort 1 (n=6), Cohort 2 (n=6), Cohort 3 (n=6), Cohort 4 (n=10)
B: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen
C: Arm Label: Nusinersen 6 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Nusinersen 12 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Nusinersen 12 mg, Nusinersen 6 mg
D: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mothers in Motion Program to Prevent Weight Gain in Overweight/Obese WIC Mothers (MIM)
Brief Summary: Mothers in Motion will draw on the successes of the pilot intervention of the same name and will promote healthy lifestyle behavior changes (eating more fruits and vegetables, increasing physical activity, dealing with stress) in low-income WIC mothers of young children. The intervention group's weight change (difference between the initial enrollment and 3 months post intervention) will differ from the control group's weight change by an average of at least 2.8 pounds.


Options:
A: Arm Label: Intervention for diet, exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational intervention for diet and physical activity | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Educational message on skin cancer awareness | Intervention Type: BEHAVIORAL; Name: Educational intervention for diet and physical activity; Assigned to Arm(s): Intervention for diet, exercise | Intervention Type: BEHAVIORAL; Name: Educational message on skin cancer awareness; Assigned to Arm(s): Control
B: Arm Label: Lifestyle Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Counseling | Arm Label: No Lifestyle Counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle Counseling; Assigned to Arm(s): Lifestyle Counseling
C: Arm Label: 10,000 step/day recommendation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 10,000 step/day recommendation | Arm Label: Adaptive recommendation; Type: EXPERIMENTAL; Interventions: Behavioral: Adaptive step recommendation | Intervention Type: BEHAVIORAL; Name: Adaptive step recommendation; Assigned to Arm(s): Adaptive recommendation | Intervention Type: BEHAVIORAL; Name: 10,000 step/day recommendation; Assigned to Arm(s): 10,000 step/day recommendation
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation
Brief Summary: In this double-blinded randomized clinical trial study, investigators assessed probiotic used to prevent or delay radiation induced grade moderate to severe diarrhea with patient treated for pelvic cancer.


Options:
A: Arm Label: octreotide + radiation; Type: EXPERIMENTAL; Interventions: Drug: octreotide acetate, Radiation: radiation | Arm Label: placebo + radiation; Type: ACTIVE_COMPARATOR; Interventions: Other: placebo, Radiation: radiation | Intervention Type: DRUG; Name: octreotide acetate; Assigned to Arm(s): octreotide + radiation | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo + radiation | Intervention Type: RADIATION; Name: radiation; Assigned to Arm(s): octreotide + radiation, placebo + radiation
B: Arm Label: CIMRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: HIMRT; Type: EXPERIMENTAL; Interventions: Radiation: radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): CIMRT, HIMRT
C: Arm Label: Fiber supplement; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Inulin and Fructo-oligosaccharide | Arm Label: Maltodextrine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrine | Intervention Type: DIETARY_SUPPLEMENT; Name: Inulin and Fructo-oligosaccharide; Assigned to Arm(s): Fiber supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrine; Assigned to Arm(s): Maltodextrine
D: Arm Label: Bifilact® probiotics standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bifilact® | Arm Label: Bifilact® probiotics high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bifilact® | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Bifilact®; Assigned to Arm(s): Bifilact® probiotics high dose, Bifilact® probiotics standard dose | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Brief Summary: The purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).


Options:
A: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: Lymphodepleting chemotherapy | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: Lymphodepleting chemotherapy; Assigned to Arm(s): Tisagenlecleucel
B: Arm Label: C-CAR011; Type: EXPERIMENTAL; Interventions: Biological: C-CAR-011 | Intervention Type: BIOLOGICAL; Name: C-CAR-011; Assigned to Arm(s): C-CAR011
C: Arm Label: HIGH DOSE CHEMOTHERAPY AND ASCT; Type: EXPERIMENTAL; Interventions: Drug: Carmustine, Drug: Etoposide, Drug: Cytarabine, Drug: Melphalan, Biological: Pegfilgrastim, Biological: 19-28z T CELLS, Procedure: Autologous Stem Cell Transplantation | Intervention Type: DRUG; Name: Carmustine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: Pegfilgrastim; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: 19-28z T CELLS; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: PROCEDURE; Name: Autologous Stem Cell Transplantation; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT
D: Arm Label: Treatment (CD20-specific CAR T cell, chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy, Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Procedure: Leukapheresis, Drug: Fludarabine Phosphate | Intervention Type: BIOLOGICAL; Name: Chimeric Antigen Receptor T-Cell Therapy; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: PROCEDURE; Name: Leukapheresis; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Treatment (CD20-specific CAR T cell, chemotherapy)

Answer: C